MESOX is creating one of the most impactful pipelines of formulated therapeutics tackling significant unmet health needs in societies worldwide.
Accelerated 505(b)(2) Pathway
Our therapeutics will reach the market faster than traditional NCEs—30 months vs 10 years—thanks to our unique carrier technologies and a Hybrid/505(b)(2) regulatory strategy.
0 Months from concept to approval
0% Faster Formulation Development and CMC
Pipeline expansion strategy
At MESOX, we focus on therapeutic asset innovation to meet global healthcare needs and emerging market demands. We collaborate with other companies, the NHS and academia to deliver new therapeutic opportunities.
We have one of the fastest growing pipelines leveraging proprietary technologies including digital formulation screening models and accelerated carrier formulation processes.